TABLE 2.

Distribution of actual clinical benefit (ACB), clinical added value (CAV), European Society for Medical Oncology—Magnitude of Clinical Benefit Scale (ESMO‐MCBS) and American Society of Clinical Oncology—Value Framework (ASCO‐VF) scores

ACB (n = 39)	Substantial	30 (76.9%)
	Moderate	4 (10.3%)
	Low	5 (12.8%)
CAV (n = 39)	I	0
	II	1 (2.6%)
	III	12 (30.8%)
	IV	15 (38.5%)
	V	11 (28.2%)
ESMO‐MCBS (n = 38)	5	4 (10.5%)
	4	20 (52.6%)
	3	9 (23.7%)
	2	2 (5.3%)
	1	3 (7.9%)
ASCO‐VF (n = 33)	80‐100	3 (9.1%)
	60‐80	6 (18.2%)
	40‐60	16 (48.5%)
	20‐40	7 (21.2%)
	0–20	1 (3.0%)

Note: For the ESMO‐MCBS score, 1/39 indication was for adjuvant therapy, which was not covered by the 1 to 5 scale. For the ASCO‐VF score, 6/39 indications were not applicable because they were based on single‐arm trials.